These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23971760)

  • 21. Fecal calprotectin and the clinical activity index are both useful to monitor medical treatment in patients with ulcerative colitis.
    Burri E; Beglinger C; von Felten S; Lehmann FS
    Dig Dis Sci; 2015 Feb; 60(2):485-91. PubMed ID: 25344905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of faecal calprotectin measurement on clinical decision-making in patients with Crohn's disease and ulcerative colitis.
    Bathe AL; Mavropoulou E; Mechie NC; Petzold G; Ellenrieder V; Kunsch S; Amanzada A
    PLoS One; 2019; 14(10):e0223893. PubMed ID: 31647834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis.
    Mosli MH; Zou G; Garg SK; Feagan SG; MacDonald JK; Chande N; Sandborn WJ; Feagan BG
    Am J Gastroenterol; 2015 Jun; 110(6):802-19; quiz 820. PubMed ID: 25964225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of fecal calprotectin in the diagnosis and treatment of segmental colitis associated with diverticulosis.
    Tursi A; Elisei W; Giorgetti G; Aiello F; Brandimarte G
    Minerva Gastroenterol Dietol; 2011 Sep; 57(3):247-55. PubMed ID: 21769075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Calprotectin concentration in stool samples as a determinant of the activity degree of inflammatory process in inflammatory bowel diseases].
    Sagynbaeva VÉ; Lazebnik LB; Efremov LI; Guseĭnzade MG
    Eksp Klin Gastroenterol; 2013; (6):35-8. PubMed ID: 24772858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin.
    Kristensen V; Klepp P; Cvancarova M; Røseth A; Skar V; Moum B
    J Crohns Colitis; 2015 Feb; 9(2):164-9. PubMed ID: 25518057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity.
    Schaffer T; Schoepfer AM; Seibold F;
    J Crohns Colitis; 2014 Sep; 8(9):1125-32. PubMed ID: 24636141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease.
    Costa F; Mumolo MG; Ceccarelli L; Bellini M; Romano MR; Sterpi C; Ricchiuti A; Marchi S; Bottai M
    Gut; 2005 Mar; 54(3):364-8. PubMed ID: 15710984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study.
    Kallel L; Ayadi I; Matri S; Fekih M; Mahmoud NB; Feki M; Karoui S; Zouari B; Boubaker J; Kaabachi N; Filali A
    Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):340-5. PubMed ID: 19581809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endoscopic Factors Influencing Fecal Calprotectin Value in Crohn's Disease.
    Goutorbe F; Goutte M; Minet-Quinard R; Boucher AL; Pereira B; Bommelaer G; Buisson A
    J Crohns Colitis; 2015 Dec; 9(12):1113-9. PubMed ID: 26351383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers.
    Ricanek P; Brackmann S; Perminow G; Lyckander LG; Sponheim J; Holme O; Høie O; Rydning A; Vatn MH;
    Scand J Gastroenterol; 2011 Sep; 46(9):1081-91. PubMed ID: 21619483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fecal Calprotectin.
    Ayling RM; Kok K
    Adv Clin Chem; 2018; 87():161-190. PubMed ID: 30342711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can calprotectin predict relapse risk in inflammatory bowel disease?
    D'Incà R; Dal Pont E; Di Leo V; Benazzato L; Martinato M; Lamboglia F; Oliva L; Sturniolo GC
    Am J Gastroenterol; 2008 Aug; 103(8):2007-14. PubMed ID: 18802997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
    Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D
    Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What is the faecal calprotectin test?
    Drug Ther Bull; 2014 Sep; 52(9):102-4. PubMed ID: 25213590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflammatory bowel disease.
    Quail MA; Russell RK; Van Limbergen JE; Rogers P; Drummond HE; Wilson DC; Gillett PM
    Inflamm Bowel Dis; 2009 May; 15(5):756-9. PubMed ID: 19107785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis.
    Xiang JY; Ouyang Q; Li GD; Xiao NP
    World J Gastroenterol; 2008 Jan; 14(1):53-7. PubMed ID: 18176961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M
    Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. S100A12: a noninvasive marker of inflammation in inflammatory bowel disease.
    van de Logt F; Day AS
    J Dig Dis; 2013 Feb; 14(2):62-7. PubMed ID: 23146044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial.
    Sandborn WJ; Panés J; Zhang H; Yu D; Niezychowski W; Su C
    Gastroenterology; 2016 Jan; 150(1):96-102. PubMed ID: 26376350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.